INmune Bio Inc. (NASDAQ: INMB)

The QualityStocks Daily Newsletter would like to spotlight INmune Bio Inc. (NASDAQ: INMB).

INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today reported positive preliminary data during a presentation at Cambridge Healthtech Institute’s Seventh Annual Immuno-Oncology Summit in Boston. To view the full press release, visit: http://nnw.fm/puDL2.

INmune Bio Inc. (NASDAQ: INMB) is a diversified clinical-stage immunology company developing novel therapies that target distinct parts of a patient's innate immune system to fight disease. Drug candidates INKmune™ and INB03 may be used to treat cancer while XPro1595 targets neuroinflammation as a cause of Alzheimer's disease. INmune Bio's product platforms utilize a precision therapy approach to promote the body's innate immune response to treat unsolved problems in medicine.

INmune Bio is the first biotechnology company to close an initial public offering (IPO) in 2019 and commence trading on The Nasdaq Capital Market. The company also received a "Part the Cloud" award from the Alzheimer's Association in 2018 which included a $1 million grant to advance INmune Bio's XPro1595 drug candidate.

INmune Bio's product pipeline targets three segments of concern:

• Alzheimer's disease/dementia claims 5.5 million patients in the United States. INmune Bio views Alzheimer's as an immunologic disease which changes the drug discovery process, changes the way clinical trials are designed, and may provide hope for patients and caregivers.
• Cancer residual disease which is expected to generate more than 1.7 million new cases yearly with an estimated 609,640 fatalities. INMB believe that converting resting Natural Killer ("NK") cells to primed NK cells, which kill cancerous cells on contact, is an important therapeutic strategy to help clear residual disease.
• Resistance to immunotherapy. By preventing the proliferation and function of cells that resist immunotherapy, patients should have a stronger immune response to cancer cells and may respond better to other cancer treatments including immunotherapy and live longer.

INmune Bio Drug Candidates and Clinical Programs

INKmune is a biologic delivery system that primes a patient's resting NK cells to kill cancer. INKmune targets residual disease for patients that have completed initial cancer therapy (surgery, radiation and/or chemotherapy) and have a low burden of disease with a high risk of relapse.

In late 2019, INKmune will start enrolling patients in a phase I/II trial for women with relapsed refractory ovarian cancer. In many patients, cancer relapse after seemingly effective cancer therapy is due to a failure of the patients own NK cells to eliminate minimal residual disease ("MRD").

Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells' ability to eliminate residual disease.

INB03 is a checkpoint inhibitor that targets myeloid derived suppressor cells ("MDSC") which can produce an immunosuppressive shield that prevents a patient's own immune system from attacking the cancer. INmune Bio is currently completing a monotherapy INB03 phase I trial in patients with advanced solid tumors. The INB03 program will transition into a combination therapy clinical program in the summer of 2019 to prepare for a phase II trial in patients resistant to checkpoint inhibitors due to increased MDSC.

Treatment with INB03 should eliminate MDSC in the tumor microenvironment to allow checkpoint inhibitors to be therapeutically effective.

XPro1595 targets the microglial immune cells of the brain that are activated in many Alzheimer's disease patients. These microglial cells are a cause of neuroinflammation that can kill nerve cells and promote synaptic dysfunction – the cause of dementia in Alzheimer's.

The three-month, phase I trial is expected to enroll 18 patients in summer of 2019. It is designed to measure traditional and novel biomarkers of inflammation in patients with mild to moderate Alzheimer's disease who have neuroinflammation. The trial is supported by a $1 million "Part the Cloud" grant from the Alzheimer's Association. Inflammation, especially chronic inflammation, is being recognized as an important part of the pathology of many diseases including cancer and Alzheimer's disease.

Management

Dr. RJ Tesi, M.D., INmune Bio co-founder, CEO and acting chief medical officer, has been a licensed physician since 1982 and a Fellow of the American College of Surgery since 1991. He received his medical degree from Washington University School of Medicine in 1982 and has served many roles in several development-stage biotech companies focused on treatment of neurodegenerative diseases, hematologic malignancies, and other inflammatory diseases.

CFO David J. Moss co-founder, has been with the company since its formation in September 2015. He holds an MBA from Rice University and a bachelor's degree in economics from the University of California, San Diego. Moss has founded, funded and taken public various companies in a variety of industries since 1995.

Mark Lowdell, Ph.D. co-founder, has served as the chief scientific officer and chief manufacturing officer at INmune Bio since the company's formation. He is a professor of cell and tissue therapy at University College London where he has led a translational immunotherapy group since 1994. He has also been a director of cellular therapy at the Royal Free London NHS Foundation Trust. He received his Ph.D. in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.

Christopher J. Barnum is director of neuroscience at INmune Bio. Barnum is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases holding multiple positions in academic and industry. His focus has been on translating inflammatory therapies into clinical treatments for neurologic diseases using a biomarker-directed approach. Barnum's research has been supported by the NIH, the Michael J. Fox Foundation, and the Alzheimer's Association. He received his Ph.D. in neuroscience from Binghamton University.

INmune Bio Inc. (OTC: INMB), closed Monday's trading session at $8.90, up 0.907029%, on 151,344 volume with 601 trades. The average volume for the last 3 months is 12,701 and the stock's 52-week low/high is $7.00/$11.50.

Recent News

• INmune Bio, Inc. (NASDAQ: INMB) Reports Positive Preliminary Data from Phase I Clinical Trial of INB03
• INmune Bio Inc. (NASDAQ: INMB) Presents Cancer Treatment Immunotherapy at Congress of International Drug Discovery Science & Technology
• INmune Bio, Inc. (NASDAQ: INMB) Co-Founder and CEO to Present at Cambridge Healthcare Institute’s Seventh Annual Immuno-Oncology Summit

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT)

The QualityStocks Daily Newsletter would like to spotlight Blue Hat Interactive Entertainment Technology (BHAT).

The toy industry is not a frivolous pastime. In fact, the toy business offers a wealth of opportunity. The United States is currently the largest segment of global toy sales. However, in terms of growth prospects, the toy market in Asia is on a tear, growing by a whopping 20 percent from 2012 to 2017. China’s market for toys and video games, now worth $45 billion, is expected to bypass America in just a few years (http://nnw.fm/2pUDX). With this expansion, modern consumers are looking for unique products that go far beyond the typical and deliver a wow factor. Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) delivers that wow factor, creating the toys and games that parents want and children enjoy. Also today, NetworkNewsWire released a report on the company detailing how BHAT is ‘One to Watch.’

Blue Hat Interactive Entertainment Technology (BHAT) is a cutting-edge creator, developer and operator of popular augmented reality (“AR”) interactive smart toys and educational games in China. Blue Hat’s mobile-connected entertainment platform connects physical items to mobile devices through wireless technologies, creating a unique interactive user experience in various mobile games, interactive educational materials and toys with mobile game features.

Blue Hat designs original toys and games that utilize augmented reality technology, motion capture technology, image recognition technology, voice control, light sense technology, infrared, levitation induction, and other trending scientific technologies to transverse the virtual with reality. Blue Hat creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. This combination provides users with a more natural form of human computer interaction, enhances a user’s perception of reality, and delivers a more immersive entertainment experience.

Proprietary Technology

Founded in 2010, Blue Hat’s proprietary technology, product research and development, marketing channels and brand operation are the cornerstones of the business. Blue Hat focuses on the combination of “online” and “offline” activity and the interaction between “entertainment” and “product” to create a high-tech entertainment platform combining mobile games and AR. With the help of computer graphics, motion capture technology, image recognition technology and visualization technologies, Blue Hat accurately “places” virtual objects into the physical world, creating a new and stimulating visual environment for users.

Blue Hat recently displayed a variety of its sci-tech products at the Guangzhou International Toy Exhibition in China including AR Racer, Elastic Bubbles, AR Space Track, AR Alloy Toy Car, AR Need a Spanking, 5D Animated Magic Aquarium, Bug Travelers, AR Picture Book and other interactive games and smart toys.

The company has multiple products in development including new generations of four primary product lines and two new product lines.

Patents and Copyrights

Blue Hat’s advanced AR technology in interactive entertainment is protected by 178 authorized patents with 44 patents in various stages of the application process.

Another 14 applications for Patent Cooperation Treaty, or PCT, have been filed for international patents. As of March 31, 2019, the company owns 645 copyrights for artwork, 71 registered trademarks and 27 software copyrights.

Sales and Marketing

There has been rapid growth in the toys and games industry in China over the last several years. Total retail sales of toys and games in China soared from RMB 111.8 billion in 2012 to RMB 276.5 billion in 2017 with an average annual growth rate of 19.9% in 2017. Blue Hat believes the company is well positioned with little competition as the toy industry rapidly shifts toward intelligent and interactive toys and games. Retail sales of electronic toys grew at 24% annually in 2017 while that of traditional toys grew at 7%.

In addition to a powerful ecommerce presence, Blue Hat has long-term relationships with partnered distributors that place the company’s AR interactive entertainment products into well-known international retail chains and retail outlets. Blue Hat’s integrated online and offline sales channels include e-commerce giants such as Amazon and Alibaba, retail chain stores and the company’s physical experience store located in Xiamen, China. Blue Hat plans to open or franchise approximately 100 additional stores in China by 2021.

Blue Hat’s community-based platform offers users a highly engaged and interactive community with online communication forums and offline social activities. The company advocates a new model of “teaching through lively activities” and combines AR technology with education, integrating its products into situational teaching, roleplaying and man-machine interaction. This novel educational experience helps realize optimal transformation of information, creating a knowledge and enhancing cognition.

Management

Director and CEO Xiaodong (Sean) Chen has over 20 years of experience creating, developing and producing toys and games related products. Chen earned his EMBA from Renmin University of China and has been chairman of the board of directors and general manager of Fujian Blue Hat Interactive Entertainment Technology Ltd. since August 2015.

CFO and Director Caifan, who has over 20 years of financial accounting and taxation experience, earned a degree in finance from Hunan University of Finance and Economics. He has served as director, deputy general manager and financial controller of Fujian Blue Hat Interactive Entertainment Technology Ltd. since August 2015.

Jianyong Cai, chief technology officer and director, has over 35 years of experience in data communication principles, communication network foundation, software engineering, communication network theory and technology and computer network architecture. He holds degrees in data communication principles, communication network foundation and software engineering from University of Science and Technology of China. He has been director, deputy general manager and chief engineer of Fujian Blue Hat Interactive Entertainment Technology Ltd. since January 2010.

Blue Hat Interactive Entertainment Technology (BHAT), closed Monday's trading session at $4.75, up 28.3784%, on 163,415 volume with 494 trades. The average volume for the last 3 months is 474,000 and the stock's 52-week low/high is $3.5999999/$6.25.

Recent News

• Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) Knows that the Toy Business is Not a Game
• Why Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) Is ‘One to Watch’
• Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) Creating Augmented Reality Toys, Games for Youth in China

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

The exploding interest in cannabis products and in new ways of enjoying them has proven fertile ground for drug technology innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) as it markets the company’s revolutionary DehydraTECH platform for increasing the absorption rates of varied edible substances, including nicotine and cannabidiol (CBD).

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECHTM technology to improve taste, remove odor, and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada, the largest-market states in the United States, and internationally. Lexaria has entered into a R&D partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea, and supplements. These brands include ViPova™ and TurboCBD™.

In 2015, Lexaria commissioned an independent third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation improve intestinal absorption as much as 500%. Lexaria has conducted multiple rounds of studies including in vivo and human clinical. In absorption studies conducted on rats, for example, Lexaria detected nicotine in the animal’s bloodstream just two minutes after it entered the stomach. In a randomized, double blinded human clinical study, cannabidiol (CBD) was measure in the human bloodstream at a 317% higher rate 30 minutes after swallowing a capsule processed with DehydraTECH than a non-enhanced capsule of equal strength.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: Hemp/CBD; Pharmaceutical; Cannabis; and Nicotine.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the end of 2018, the company’s patent portfolio includes 53 patent applications filed and pending in more than 40 countries around the world; and 10 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally in 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third-partners and has signed royalty deals with start-up companies as well as with a Fortune 100. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Monday's trading session at $0.75, up 7.5256%, on 75,934 volume with 57 trades. The average volume for the last 3 months is 80,022 and the stock's 52-week low/high is $0.600000023/$2.24.

Recent News

• Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Paves Way for New Cannabis Brand, B2B Sales through Partnership with Alcohol-Free Beverage Maker
• Lexaria Bioscience Engages Integra Consulting Group to Provide Investor Relations Services
• Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Summarizes DehydraTECH(TM) Technology Licensees

Nightfood Holdings, Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings, Inc. (NGTF).

Nightfood Holdings, Inc. (OTCQB: NGTF) was featured today by Virtual Investor Conferences, the leading proprietary investor conference series, which today announced that the presentations from the August 1, 2019 OTCQB Venture Company Conference are now available for on-demand viewing at VirtualInvestorConferences.com. https://tinyurl.com/Aug1VIC-AgendaPR.

Nightfood Holdings, Inc. (OTCQB: NGTF), a pioneering consumer goods brand development company headquartered in Tarrytown, New York, owns Nightfood, Inc., creator of delicious, award-winning and better-for-you ice cream formulated by sleep and nutrition experts, and its wholly owned subsidiary MJ Munchies, Inc., which seeks to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. Known as “The Nighttime Snack Company,” Nightfood Inc. is focused on improving the late-night snacking choices of consumers while solving America’s $50 billion-dollar nighttime snacking problem.

Nightfood Ice Cream

Nightfood’s higher-protein and sleep-friendly ice cream won the 2019 Product of the Year Award in a survey of over 40,000 consumers. The annual Product of the Year survey, the world’s largest consumer-voted award for product innovation, is conducted by Kantar, a global leader in consumer research. In beating out the other finalists, consumers indicated that Nightfood’s one-of-a-kind innovation and unique value proposition made it a clear-cut winner in the ice cream space and a brand they were highly motivated to try. Winners of the 32-year-old award have been shown to outperform category sales performance by over 38 percent.

Less than two months since manufacturing their first pint of ice cream, Nightfood has now secured distribution in more than 13 states, and has received extensive media coverage from outlets such as USA Today, Fox Business’ Mornings With Maria, Parents Magazine, The Food Network, MarketWatch, The Washington Post, Business Insider, Bustle, and more.

With the Product of the Year award and millions in media coverage, Management has publicly stated their goal of securing nationwide distribution in over 10,000 retail outlets by March 31, 2020.

Formulated by leading sleep and nutrition experts, including America’s most prominent sleep expert, Dr. Michael Breus, Nightfood’s higher protein/higher fiber, and lower sugar ice cream delivers great ice cream taste and texture, while minimizing sleep-disruptive ingredients such as caffeine, excess sugar, and excess fat and calories. The addition of certain minerals, enzymes and amino acids, which research suggests can support sleep quality, is another bonus. Nightfood only uses hormone-free milk, is certified Kosher, and offers eight original flavors, five of which are gluten-free. Nightfood ice cream also uses all-natural sweeteners with no Erythritol, no sucralose, or other artificial sweeteners.

More than 37,000 consumers across the country have already requested coupons for the company’s newly launched Nightfood ice cream by entering a giveaway hosted at NightfoodIceCream.com which includes a chance to win a one-year supply (96 pints) plus a freezer for storage. The coupon program is being run in conjunction with PromotionPod, which has previously conducted successful campaigns for brands such as Chobani, Halo Top, and BodyArmor.

Nightfood Inc. began its nationwide rollout of Nightfood ice cream in February 2019, successfully securing placement in Meijer supermarket locations in the Midwest with a concentration around the metropolitan areas of Chicago, Detroit, Indianapolis, Columbus and Milwaukee. A distribution agreement with New England Ice Cream Corporation (NEIC) will also place Nightfood ice cream in outlets located throughout Massachusetts, Vermont, New Hampshire, Maine, Rhode Island and Connecticut.

Ice cream lovers in northern California will find Nightfood Ice Cream at various upscale, independent retail outlets in and around the San Francisco bay area serviced through a distribution agreement with Wonder Ice Cream Company, which services thousands of retail outlets from Bakersfield north to the Oregon border. Consumers can also purchase Nightfood ice cream online at BuyNightfood.com through the Company’s partnership with IceCreamSource.com.

Ice cream is now the 2nd most popular night snack choice, with almost half of all consumers reaching for ice cream after dark. According to IRI Worldwide, 44 percent of all snack consumption occurs between dinner and bedtime, representing a consumer spend of over $1 billion weekly on nighttime snacks in the U.S. alone. Market research giant Mintel recently released a report identifying nighttime specific food and beverages as one of their most “compelling and category changing” trends for 2017 and beyond.

Nightfood has developed a dynamic infographic resource that clearly illustrates the size and scope of the largely untapped nighttime snack category (http://NightSnacking.com). Americans everywhere are likely to identify with the infographic’s results that vividly illustrate late night snacking by age group, popular snack choice, and amount of money spent each week on feeding after-hour snack attacks. Available in eight delicious flavors, Nightfood ice cream can help consumers satisfy nighttime cravings in a better, healthier, more sleep-friendly way.

MJ Munchies, Inc.

MJ Munchies, Inc., was formed in 2018 as a new, wholly owned subsidiary of Nightfood Holdings, Inc. to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. The Company intends to market some of these new products under the trademarked brand name “Half-Baked” and has entered into a Letter of Intent that allows Global Consortium Inc. (OTC: GCGX) subsidiary Infused Edibles to receive an exclusive license to manufacture and distribute marijuana and CBD-infused products under the Half-Baked brand.

Management believes the Half-Baked brand will give the Company a unique and defensible competitive advantage against other recreational edible brands. The Company believes tremendous opportunities currently exist to launch successful and legally compliant products in this space, and that such opportunities will continue to grow over time.

Management Team

Nightfood founder and CEO Sean Folkson is a formerly frustrated nighttime snacker whose late-night cravings led him to seek a better solution for himself and others through the creation, marketing and distribution of the Nightfood product line. Folkson also founded internet marketing company AffiliatePros.com which provided the startup capital to launch Specialty Equipment Direct, an online distributor of floor removal equipment that quickly grew to 7-figure revenues. Folkson received a bachelor’s degree in business administration with a concentration in marketing from S.U.N.Y Albany, New York, in 1991.

Jim Christensen, vice president of Nightfood Ice Cream, is the former Vice President of Ice Cream Sales with global ice cream giant Unilever. In his over 20 years at Unilever, Jim led sales and distribution initiatives for brands such as Ben & Jerry’s, Klondike, Breyers and Good Humor. Christensen joined the Nightfood team in June of 2018 with the directive to launch Nightfood ice cream rapidly into national distribution through supermarket, drug, convenience and other channels. Understanding that the overwhelming majority of at-home ice cream consumption occurs in the hours before bed, Christensen has identified Nightfood as the next evolution in better-for-you ice cream.

CFO Mark Noffke, CPA, has over 37 years of experience as a seasoned financial and management professional. He has served as chief financial officer of several small cap public companies since 2004 where he oversaw virtually every aspect of the company’s operations, administration, customer service and human resources. Noffke has a bachelor’s degree in accounting from Valparaiso University in Indiana.

Advisory Board

The Nightfood advisory board includes Tom Morse, founder of 5-Hour Energy and Living Essentials, LLC.; Doron Stern, former vice president of marketing at Chobani and Popcorn, Indiana; restaurateur and celebrity Chef Chris Santos; Paul Jarrett, CEO of fast-growing nutrition startup BuluBox; Eric Egeland, president of Capacity Consulting Inc.; Dr. Michael A. Grandner, director/Sleep and Health Research Program at the University of Arizona; Dr. Michael Breus, sleep expert and best-selling author known to millions as The Sleep Doctor(TM); Dr. Lauren Broch, resident nutrition, sleep disorder expert and a member of the scientific advisory board.

Nightfood Holdings, Inc. (NGTF), closed Monday's trading session at $0.44, even for the day, on 101,643 volume with 32 trades. The average volume for the last 3 months is 189,007 and the stock's 52-week low/high is $0.160099998/$0.920000016.

Recent News

• OTCQB Venture Company Investor Presentations Now Available for On-Demand Viewing
• Live OTCQB Venture Company Investor Conference August 1st
• Nightfood to Present at VirtualInvestorConferences.com on August 1, 2019

Grapefruit Boulevard Investments Inc. (IGNG)

The QualityStocks Daily Newsletter would like to spotlight Grapefruit Boulevard Investments Inc., the wholly owned subsidiary of Imaging3 Inc. (IGNG).

California-based Grapefruit Boulevard Investments, a wholly owned subsidiary of Imaging3 (OTCQB: IGNG), this morning announced the launch of its unique line of newly formulated and flavored cannabis oil infused CDB and THC vaporization cartridges branded as “Rainbow Dreams.” To view the full press release, visit: http://nnw.fm/U0YQn. Also today, the company announced it has filed a registration statement with the SEC on Form S-1 to register shares of the company’s common stock underlying the $600,000 convertible note recently issued to an institutional investor, as well as other securities to be issued to the investor (http://nnw.fm/muLT6).

Grapefruit Boulevard Investments Inc., a California corporation (“Grapefruit”), as of May 31, 2019, is a wholly owned subsidiary of Imaging3 Inc. (OTC: IGNG), a Delaware corporation whose shares of $.001 par value common stock are publicly traded on the OTCMarkets OTCQB Market under the symbol “IGNG.” IGNG is subject to the reporting requirements of the Securities Exchange Act of 1934 and files annual and quarterly reports pursuant thereto. Grapefruit holds licenses originally issued by the State of California in January 2018 to both manufacture and distribute cannabis products. Grapefruit’s management now owns a controlling interest in IGNG which now owns 100% of Grapefruit’s outstanding shares. As a result, IGNG’s financial reports will consolidate both IGNG’s and Grapefruit’s balance sheet, statement of operation and statement of cash flows and IGNG and Grapefruit will be operated as a single company. IGNG intends to change its name to Grapefruit and to obtain a more appropriate trading symbol as soon as possible. Hereinafter the combined companies will be referred to as “Grapefruit” or the “Company.”

Grapefruit’s corporate headquarters is in Westwood, Los Angeles, California. Grapefruit holds licenses to both manufacture and distribute cannabis products which were originally issued in January 2018 and is fully compliant with all applicable laws and regulations to operate its cannabis manufacturing and distribution businesses.

The company is well-focused on sourcing only the “best of the best” raw cannabis materials to create the highest quality, most-trusted and consistent recreational and medical cannabis products for its customers. Grapefruit is committed to ensuring class-leading quality by rigorously testing the purity and potency of its raw materials throughout the manufacturing process and distribution chain.

Grapefruit owns and operates its fully licensed and compliant ethanol extraction laboratory located in the Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, California. The company’s extraction lab produces high quality, cannabis-derived distillate, also known as “honey oil,” from cannabis flower and “trim.” THC honey oil is one of base cannabis commodities which serves as the active ingredient in everything from infused edibles and tinctures/creams to the cartridges used in vapes and e-cigarettes. Honey oil often sells on the wholesale marketplace for thousands of dollars per liter, with pricing being dependent on quantity purchased, as well as other market factors such as the availability and cost of the underlying flowers and/or trim.

Grapefruit began its extraction operations in May 2019. Plans are in place to expand its honey oil production through the purchase of additional distillation equipment, which is expected to significantly increase the company’s production capacity by the fourth quarter of 2019. Grapefruit’s extraction lab is fully scalable and expansion will be built-out on a two-acre lot owned by Grapefruit at the Coachillin’ site adjacent to its current manufacturing and distribution operation.

Grapefruit selected the City of Desert Hot Springs for its cannabis extraction laboratory, because the city has created a friendly business environment for cannabis-based manufacturers, including incentives like the absence of taxes on cannabis oil production revenues. This affords Grapefruit a fundamental competitive market advantage over other Honey Oil producers.

The California cannabis regulatory scheme is unique in that it requires all cultivators (cannabis farms) and manufacturers (whether producing oils/distillates, infused edibles, tinctures creams or other cannabis products) to sell their products into the legal cannabis wholesale and retail markets exclusively through licensed distributors such as Grapefruit. Grapefruit initially obtained its California recreational and medicinal cannabis distribution license Jan. 4, 2018. In May 2019, Grapefruit was granted its provisional distribution license which is renewable annually, thereby cementing the regulatory foundation necessary to rapidly expand its distribution business.

Grapefruit’s distribution license affords it a twofold strategic advantage: first, to market and sell its own cannabis product lines to retailers throughout California; and second, to buy and resell bulk cannabis flowers and trim as well as all other legal cannabis products to properly licensed distributors and/or retailers throughout California.

The Coachillin’ Canna-Business Park, home to Grapefruit’s current operating facilities and adjacent two-acre parcel of land, is a 160-acre, self-contained legally mapped compound providing the Company with a fully permitted and serviced physical plant from which Grapefruit intends to establish a leading position in the booming California cannabis sector. The parcel was purchased by the Company prior to the Park’s full development, and the value of the land the Company owns has conservatively since doubled in value to over $2 million. Additional long-term benefits of the Coachillin’ compound include agricultural rates for power, which are currently $0.09 per kilowatt hour; the Park’s deep-water well that fully satisfies its need for water; and security expenses shared by all resident businesses. The Coachillin’ Park’s promoters also plan to position the Park, located only 10 miles north of rapidly growing uptown Palm Springs and less than 15 miles from the site of the Coachella and Stagecoach music festivals as a must-see canna-tourism destination.

Grapefruit’s ultimate goal is to become a vertically integrated, seed-to-sale cannabis and CBD product company serving the California market. Moreover, it plans to roll-out its product lines in other states, such as Nevada, Illinois, Oregon, Colorado and Washington. Grapefruit has plans to build a large, all-inclusive facility that will house a 50,000-square-foot-plus indoor grow canopy, a large extraction laboratory designed to extract both THC and CBD cannabinoids via non-volatile (ethanol) and volatile (butane) processes, a manufacturing space to produce Grapefruit’s vape lines and CBD products, an FDA-certified kitchen for the production of Grapefruit edibles and a distribution facility to sell all products into the entire cannabis market. The indoor grow canopy operation will be outfitted and operated to produce ultra-high-quality flowers and buds, some of which, along with the high-quality trim resulting from cleaning and maintaining the grow, will provide biomass necessary to feed the company’s extraction laboratory. Fueled by this hand cultivated biomass, Grapefruit’s lab will continuously produce pesticide and heavy metal-free world class honey oil to both serve as the active ingredient in all of Grapefruit’s branded and unbranded products and meet the projected ever-growing demand for high quality honey oil in the California market.

Grapefruit’s motto – A High You Can Trust – embodies its philosophy and ethos, reminding consumers of the company’s commitment to manufacturing, procuring and distributing only the highest quality all-natural cannabis flower, concentrates and related products that are free from pesticides, heavy metals and bacteria. Grapefruit will target its products to all recreational cannabis enthusiasts’ as continuous, consistent cannabis products. By relentlessly adhering to these policies Grapefruit intends to become the Titleist of the Cannabis industry, known for unwavering quality and consistency.

Grapefruit is managed by a team of experts possessing the experience, skill and resources required to succeed in the competitive cannabis marketplace. Founded by brothers Bradley Yourist, CEO, and Daniel Yourist, COO, Grapefruit has expanded to become a group of industry professionals sharing a passion for all things cannabis. Both the CEO & COO are attorneys licensed to practice law the State of California who possess expert cannabis licensing and regulatory expertise and experience, which will allow Grapefruit to deftly navigate the ever changing California regulatory landscape and apply for new cannabis licenses at reduced costs when necessary, rather than having to acquire licenses that are often overvalued and/or pay outside counsel to handle such matters.

Grapefruit also has its own line of cannabis-infused concentrates and edibles. Among the brands now in stores or soon to be launched are:

• Rainbow Dreams is a new lifestyle brand designed specifically for the recreational cannabis marketplace. The Rainbow Dreams brand captures the anything goes party vibe of the 1970s by offering an array of cannabis products, such as a line of vape carts with unique cannabis strains combined with all-natural flavors for a superior no-burn experience. Rainbow Dreams fills an important niche in the marketplace as a top shelf quality product line that is competitively priced.
• Sugar Stoned, which Grapefruit acquired in the winter of 2018, has always been a popular cannabis edibles brand which terminated operations when recreational cannabis became legal and required a license in California. Grapefruit purchased the Sugar Stoned brand in 2019 and it is now a Grapefruit portfolio brand consisting of a premium quality cannabis-infused gummy line with eight different flavors: blue raspberry, cherry, grape, peach, pineapple, sour apple, strawberry and watermelon. Grapefruit intends to expand the brand in the near future through the release of a variety of infused cookies.

Grapefruit Boulevard Investments Inc. (IGNG), closed Monday's trading session at $0.08, even for the day, on 52,195 volume with 8 trades. The average volume for the last 3 months is 150,403 and the stock's 52-week low/high is $0.006095/$0.358999997.

Recent News

• Grapefruit Boulevard Investments Inc. (IGNG) Launches “Rainbow Dreams” – A New Line of Flavored CBD THC Oil Infused Vaporization CCell Cartridges
• Grapefruit Boulevard Investments Inc. (IGNG) Files Registration Statement, Anticipates Funding of Second Tranche
• Imaging3, Inc./Grapefruit Announces Filing of Registration Statement

Spectrum Global Solutions, Inc. (SGSI)

The QualityStocks Daily Newsletter would like to spotlight Spectrum Global Solutions, Inc. (SGSI).

Spectrum Global Solutions (OTCQB: SGSI), together with its subsidiaries, is well-positioned amid the evolving infrastructure and continuing maintenance needs in the telecommunication industry. To view the full article, visit: http://nnw.fm/P3u4n.

Spectrum Global Solutions, Inc. (SGSI) is a leading single-source provider of end-to-end, next-generation wireless and wireline network infrastructure services and staffing solutions to the service provider (carrier) and corporate enterprise markets across the United States, Canada, Puerto Rico, Guam and the Caribbean. Spectrum Global Solutions provides services directly to carriers, aggregators, utilities, enterprise, Project Management Organizations (PMO) and Original Equipment Manufacturers (OEM) clientele through the following subsidiaries:

• AW Solutions, Inc. and AW Solutions Puerto Rico, LLC – Provides best-in-class communications infrastructure deployment services to carriers, OEMs, PMOs, utilities and enterprise clients by offering discrete and full turnkey service solutions for wireless and wireline clientele. AW Solutions holds professional engineering licenses in all contiguous states and in the District of Columbia and Hawaii; the Canadian provinces of British Columbia, Quebec, Ontario, Alberta and Newfoundland and Labrador; in Puerto Rico, Guam and the U.S. Virgin Islands.
• ADEX Corporation and ADEX Puerto Rico, LLC – An international service organization providing turnkey services and staffing solutions to telecommunications carriers and enterprise clients. Since 1993, ADEX has been assisting telecommunications companies throughout the project life cycle of any network deployment. ADEX and its service capabilities extend from the most basic installation functions to the most advanced engineering disciplines for today and tomorrow’s communications networks. Headquartered in Atlanta, Georgia, ADEX employs technical professionals and provides infrastructure services worldwide via domestic and international locations.
• Tropical Communications, Inc. – A state licensed electrical and underground utility contractor headquartered in Miami, Florida, providing all types of communications and infrastructure facility structured wiring services and solutions since 1984.

Through its subsidiaries, Spectrum Global Solutions is a comprehensive single-source provider for professional services and solutions for the development, deployment and maintenance of wireless/Distributed Antenna System (DAS)/small cell/wireline and fiber networks and infrastructure. The company’s services range in scope from a single activity to multiyear, multi-region, large-scale turnkey development contracts with a deepening pool of international, national, regional and local projects. Spectrum Global Solutions has completed more than 150,000 project activities on wireless, DAS, wireline and fiber networks across the United States utilizing licensed professional engineers, project managers, technicians and general contractors.

Market Opportunity

Growth projections for the telecom industry show a high growth cycle 2018 through 2025 with a four-fold increase in domestic mobile data traffic and up to $150 billion in fiber investment over the next 5-7 years (Deloitte, 2017). The worldwide explosion of smart phones, tablets and BYOD by customers demanding rapid deployment of new apps, private networks with better coverage and enhanced capacity provides a compelling enterprise opportunity market. The imminent rollout of 5G next generation networks, IOT (Internet-Of-Things) technology deployments, the FirstNet national public safety system, small cell/network densification, Dish Network Deployment, fiber and infrastructure network builds for backhaul and expanded deployments, new FCC spectrum auctions and upgrades to 4G, DAS and small cell networks are contributing to a projected $157 billion in U.S. telecommunication carrier capital expenditures by 2021.

Management

CEO Roger Ponder has served as a director of Spectrum Global Solutions since April 2017. Ponder served as President/CEO of Summit Capital Advisors, LLC, and Summit Broadband, LLC a provider of consulting services to private equity and institutional banking entities in the telecommunications, cable and media/internet sectors. He also served as a member of the board of directors of InterCloud Systems, Inc. and served as its Chief Operating Officer from November 2012 to March 2015. Prior to that Ponder retired from Time Warner Kansas City Division as President/CEO. Ponder brings extensive business development, strategic planning and operational experience to the Company.

Keith Hayter is President of Spectrum Global Solutions and has served as a director of the Company since April 2017. Hayter has also served as the Chief Executive Officer and President of AW Solutions Inc. and AW Solutions Puerto Rico LLC since November 2006. He was Vice President and General Manager of Alcoa Wireless Services from 2001-2006. Hayter served in both the U.S. and British armies and brings extensive multi-national experience in the start-up, development, management and growth of companies in the telecommunication, engineering and construction industry.

Spectrum Global Solutions, Inc. (SGSI), closed Monday's trading session at $0.036, even for the day, on 1 volume with 1 trade. The average volume for the last 3 months is 127,337 and the stock's 52-week low/high is $0.032000001/$2.5999999.

Recent News

• Spectrum Global Solutions Inc. (SGSI) Thriving in Evolving Telecommunications Industry
• Spectrum Global Solutions Inc. (SGSI) Eyes Future Growth Following WaveTech GmbH Acquisition
• Evolving Telecommunications Industry Providing Fertile Ground for Spectrum Global Solutions Inc. (SGSI) and its End-to-End Network Services

Youngevity International, Inc. (NASDAQ: YGYI)

The QualityStocks Daily Newsletter would like to spotlight Youngevity International, Inc. (YGYI).

Youngevity International, Inc. (NASDAQ: YGYI) was featured today in the 420 with CNW by CannabisNewsWire. An interoffice memo sent to all Department of Public Safety officers in Texas instructs the members of the largest law enforcement agency in the state to stop arresting suspects on marijuana possession charges. This communication marks the most recent twist in the confusion surrounding marijuana law enforcement after lawmakers passed a law legalizing industrial hemp.

Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that includes e-commerce and the power of social selling. Among the Top 100 Global Direct Selling Companies, Youngevity offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, and a range of innovative services. Created through the 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company, today’s Youngevity International Inc. is a virtual worldwide Main Street of products and services under one corporate entity that supports a healthy and empowered lifestyle.

Youngevity International is dedicated to improving lifestyles through the universal desires of vibrant health and flourishing economics. Catering to health-conscious consumers, Youngevity believes that combining the best of the direct selling industry with the fundamentals and capabilities of a traditional business model will maximize shareholder value. The company’s Nutritional, Lifestyle and Telecommunications products and services are distributed through a global network of Preferred Customers and Distributors.

Youngevity’s wholly owned CLR Roasters LLC business line offers quality branded and private label coffee to retail stores, office coffee services, hospitality, food services, distributors, convenience, petrol stores and vending businesses. Today, CLR Roasters is the largest coffee provider for cruise lines in North America and the second largest roaster in the state of Florida. Producing a consistent premium product with superior taste, CLR Roasters has earned numerous certifications that demonstrate the company’s commitment to the craft of providing the highest quality coffee products using the best practice standards available.

Youngevity, operating in the direct-selling channel, is rapidly expanding its product and distributor base through acquisitions and mergers under an innovative concept called “the Network Cloud” that provides other direct selling companies with a home base. The company’s YoungevityGO2 mobile distributor app, a new technology-driven web platform supporting expansion of global e-commerce and social selling platforms, is available on Google Play and the App Store. In addition to the Network Cloud concept, Youngevity International owns CLR Coffee Roasters which operates a traditional coffee roasting business offering a JavaFit® gourmet product line that vertically integrates with Youngevity and its growing network of direct marketers.

Youngevity International offers more than 1,000 high quality, technologically advanced products under the following categories:

• Health and Nutrition
• Home and Family
• Food and Beverage
• Spa and Beauty
• Fashion
• Essential Oils
• Photo and scrapbooking
• Services for Home and Business

Youngevity International Inc. has compiled a best-in-class management team with a strong track record of success in private and public companies. Steve Wallach, CEO, has nearly two decades of sales and network marketing experience and has successfully guided Youngevity International Inc. to become an international, publicly-traded direct marketing company positioned for worldwide growth. Dave Briskie, president and CFO, has shepherded the company’s development into a fully vertical coffee roasting and distribution company that owns the direct marketing brand JavaFit® and the retail brand, Café La Rica.

Youngevity has also attracted a stunning group of Brand Evangelists who endorse its products. Among these are actress, author and well-known health and wellness activist Marilu Henner; former NBA basket player, Mike “Stinger” Glenn; former NFL wide receiver Drew Pearson; “Greatest Natural Bodybuilder in the World” Gene Nelson; and WNBA champion, Olympic gold medalist Delisha Jones.

Youngevity International, Inc. (NASDAQ: YGYI), closed Monday's trading session at $4.44, off by 4.5161%, on 68,907 volume with 386 trades. The average volume for the last 3 months is 103,084 and the stock's 52-week low/high is $3.56999993/$16.25.

Recent News

• 420 with CNW – Texas State Police Memo Instructs Officers to Stop Cannabis Possession Arrests
• Youngevity International Inc.’s (NASDAQ: YGYI) CLR Roasters Hires Industry Veteran Omar Peraza
• 420 with CNW – Michigan Caregivers Grow More than a Million Marijuana Plants

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences (OTCQB: PBIO) recently launched its BaroShear K45 system which is based on the company’s proprietary Ultra Shear Technology (“UST”) platform. The innovative system has been optimized for the unique purpose of producing high quality, water-soluble nanoemulsions of CBD oil in water (http://nnw.fm/Gr7D4). To view the full article, visit: http://nnw.fm/CA5tF.

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Monday's trading session at $2.75, off by 6.7797%, on 17,487 volume with 46 trades. The average volume for the last 3 months is 8,588 and the stock's 52-week low/high is $1.51999998/$4.0999999.

Recent News

• Pressure BioSciences Inc. (PBIO) Solves CBD Water-Solubility Problem with Patented UST Platform
• Pressure BioSciences Inc. (PBIO) Provides Proprietary Benchtop UST Instrument to Ohio State Scientists
• Pressure BioSciences Inc.’s (PBIO) Entry into CBD Market Aims Next-Gen Nanoemulsification Platform at Critical Water-Solubility Issues

Cannabis Strategic Ventures, Inc. (OTCQB: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures, Inc. (OTCQB: NUGS).

Cannabis Strategic Ventures, Inc. (NUGS) was featured today in the 420 with CNW by CannabisNewsWire. An interoffice memo sent to all Department of Public Safety officers in Texas instructs the members of the largest law enforcement agency in the state to stop arresting suspects on marijuana possession charges. The interoffice memo, written on July 10, came barely a week before the top Republican leaders in the state (the governor, lieutenant governor and assembly leader) wrote a letter castigating the prosecutors who had either dropped or put marijuana possession cases on hold because of the law legalizing hemp.

Cannabis Strategic Ventures, Inc. (OTCQB: NUGS), headquartered in Los Angeles, California, is focused on supporting entrepreneurial growth within the fast-growing legal cannabis sector. Through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. The company also pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations, and branded products within the cannabis space.

The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.

Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.

Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.

Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.

Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.

Cannabis Strategic Ventures Pure Applied Sciences subsidiary, has a cannabis concentrate extraction services agreement with CP Logistics LLC (“CPL”), a wholly owned U.S. subsidiary of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF). Under this agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for Pure Applied Sciences under the Pure Organix brand name.

The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.

Cannabis Strategic Ventures, Inc. (OTCQB: NUGS), closed Monday's trading session at $0.32, off by 6.4601%, on 55,133 volume with 41 trades. The average volume for the last 3 months is 85,422 and the stock's 52-week low/high is $0.284999996/$5.94000005.

Recent News

• 420 with CNW – Texas State Police Memo Instructs Officers to Stop Cannabis Possession Arrests
• 420 with CNW – Senate Could Hold Hearings on Cannabis Banking Later this Month
• Cannabis Strategic Ventures in Final Negotiations to Significantly Expand Cannabis Cultivation and Retail Operations

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Marijuana Company of America Inc. (OTCQB: MCOA), an innovative hemp and cannabis corporation, continues to expand its portfolio with new products and avenues of customer service. As pioneers in the cannabis industry, dating back to 2009 when MCOA CEO Don Steinberg founded the first marijuana company ever to trade on a U.S. stock market (Medical Marijuana Inc.), MCOA has stayed at the forefront of the cannabis and hemp industry.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed Monday's trading session at $0.0042, off by 17.1598%, on 11,205,041 volume with 247 trades. The average volume for the last 3 months is 8,898,088 and the stock's 52-week low/high is $0.004/$0.039299998.

Recent News

• Marijuana Company of America Inc. (MCOA) Expands hempSMART Product Line, Begins Signups for Disruptive Cannabis Delivery Service
• Marijuana Company of America Inc. (MCOA) Provides Update on Proposed Reverse Stock Split
• Marijuana Company of America Issues Update on Proposed Reverse Stock Split

Willow Biosciences Inc. (CSE: WLLW)

The QualityStocks Daily Newsletter would like to spotlight Willow Biosciences Inc. (CSE: WLLW).

Willow Biosciences Inc. (CSE: WLLW) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. The company’s cannabidiol (“CBD”) yeast-based biosynthesis program produces a high yield, ultrapure, low-cost and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.

The company is headquartered in Calgary, Alberta, Canada.

Biosynthesis Platform

Willow’s proprietary yeast-based lab strains produce CBD, tetrahydrocannabinol (“THC”), and cannabigerol (“CBG”), as well as certain minor and novel cannabinoids.

The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by Chief Scientific Officer Dr. Peter Facchini, Willow’s research team discovered and patented numerous previously unknown genes coding for core catalytic pathway enzymes, as well as a number of additional non-pathway, yet commercially-essential, accessory genes.

Utilizing this proven synthetic biology platform, Willow’s research team has already begun producing cannabinoids at lab scale, using yeast as the host cell “factory.” This biosynthetic fermentation-based process is capable of producing pharmaceutical grade CBD in 10 days – far less time than traditional plant-based extraction methods.

Willow anticipates its technology can be scaled to produce hundreds of kilograms per batch of cannabinoid API at less than $1,000 per kilogram, thus costing approximately 60% less than current chemical synthesis methods and 90% less than conventional plant-based extraction methods.

World-Class Collaboration

Willow and Noramco Inc., the world’s largest producer of high-quality synthetic cannabinoid APIs and other controlled substance APIs for the pharmaceutical and healthcare industry, have an exclusive, worldwide Joint Development Agreement (“JDA”) to design a yeast-based biosynthesis platform for the production and distribution of a highly pure CBD isolate.

The mutually exclusive agreement calls for Willow to be responsible for optimizing yeast strains in a biosynthetic process to generate ultrapure CBD at high yield and substantially lower cost compared to current methods. Noramco will leverage its decades of experience in producing and delivering CBD and pharmaceutical APIs by being responsible for the scale-up, regulatory submission, marketing and distribution of products manufactured under the JDA.

Each company will invest comparable funds, will retain the intellectual property associated with their respective scopes of work and share equally in gross profits from sales of products manufactured under the JDA.

Market Opportunity

The agreement with Noramco (http://nnw.fm/Mz1vW) addresses the increasing demand for CBD-based APIs and other CBD-infused products by pharmaceutical, nutraceutical, consumer packaged goods, beverages and other industry sectors.

The U.S. market potential of cannabinoids is significant, with industry analysts projecting $50 billion in cannabinoid-based pharmaceutical sales and $16 billion in CBD consumer goods retail sales by 2025. As of June 2019, 34 U.S. states and the District of Columbia, Guam, Puerto Rico and U.S. Virgin Islands have legalized cannabis for medical use. Another 13 states and territories have approved recreational cannabis for adult use while other states are considering similar measures.

The cannabinoid API market continues to evolve with CBD and other cannabinoid-based treatment options currently in clinical trials for indications such as post-traumatic stress syndrome, epilepsy, Parkinson’s disease, chronic pain, schizophrenia, cancer treatments and other challenging unmet medical conditions.

Capitalization

Willow is fully funded after raising $29 million via private placement and $8 million in exercised warrants by Tuatara Capital Fund II, L.P. Proceeds of the funding will be used to enhance the existing laboratory space in Calgary and Vancouver, Canada, and in San Francisco, California. The company anticipates exiting 2020 with $15.8 million in cash.

Leadership

President and CEO Trevor Peters is an experienced executive who co-founded four startup companies in the past 15 years. He has raised over $1 billion in equity and debt financings at various stages of corporate development and has been integral to successful transactions totaling over $4 billion on sale. Mr. Peters previously was chief financial officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.

Chief Financial Officer Travis Doupe has over 18 years of experience in financial leadership roles, principally in the international oil and gas industry, where he provided corporate strategic direction while overseeing all aspects of financial operations. Mr. Doupe is the treasurer and a member of the board of directors of the Canada Council for the Americas – Alberta and holds a CA-CPA designation and earned a bachelor’s degree in management from the University of Calgary.

Dr. Peter Facchini, Chief Scientific Officer, has been professor of plant biochemistry in the Department of Biological Sciences at the University of Calgary since 1995. He is recognized internationally as a leader in plant specialized metabolite biosynthesis. Dr. Facchini is the Canada Research Chair in Plant Metabolic Processes Biotechnology and has published more than 150 research papers and scholarly articles. Dr. Facchini received a PhD from the University of Toronto and conducted postdoctoral research at the University of Kentucky and Université de Montréal.

Dr. Joseph Tucker, Executive Chairman of the Board of Directors, holds more than 20 issued or pending patents and is a member of the Board of Directors of BioAlberta. He has extensive senior leadership experience in multiple public and private biotech companies. Dr. Tucker received a PhD in biochemistry and molecular biology from the University of Calgary.

Willow Biosciences Inc. (CSE: WLLW), closed Monday's trading session at $0.82, up 12.33%, on 47,868 volume with 29 trades. The average volume for the last 3 months is 69,614 and the stock's 52-week low/high is $0.649999976/$5.25.

Recent News

• New Cannabis Stocks Added to Investor Ideas
• Investor Ideas Potcasts, Cannabis News and Stocks on the Move: Special Interview with Trevor Peters of Willow Biosciences
• 420 with CNW – Michigan Caregivers Grow More than a Million Marijuana Plants

Nabis Holdings (CSE: NAB) (OTC: NABIF) (FRA: 71P)

The QualityStocks Daily Newsletter would like to spotlight Nabis Holdings (OTC: NABIF).

Nabis Holdings (CSE: NAB) (OTC: NABIF) (FRA: 71P), dba Innovative Properties Inc., is a Canadian investment company pursuing interests in high-quality cash-flow assets in real property, securities, cryptocurrency and all branches of the cannabis sector. The company's focus on strategic revenue generation, EBITDA and growth is enshrined in its moto, "One team. One goal," and is reflected in its name: "Na bis," which is defined as, "repeat performance" or "encore."

Strategy

While the Nabis' targets span numerous industries, the company aims to establish an Anchor Investment Portfolio primarily through the acquisition of majority interests in high quality U.S. cannabis assets and brands that have achieved cash flow. The company will then employ a hands-on approach to assist the investee in implementing standards and consistency to enhance their operations.

Criteria for investment targets are as follows:

• Positive EBITDA, vertically integrated operators in limited license states with large addressable markets
• Emphasis on operations that add material EBITDA within 12 months with enhanced access to capital and Nabis' value add approach on operations and brand consistency
• Identifying proven operators with good expertise to add value to a consolidation strategy
• Focused on MSOs (Multi-state Operators) with strong brand traction
• Pharma grade cultivation, extraction, dispensaries and other addressable operations

Current Endeavors

Nabis has completed investments in five Michigan properties with Cannabis provisioning, processing and cultivation licenses. The Company has also entered into binding Letters of Intent ("LOI") to invest in vertically integrated assets in Michigan, Arizona and Washington State. The company's goal is to be invested in four to five additional states in the coming months.

Arizona – LOI to acquire full control of Organica Patient Group Inc. ("OPG") and RDF Management Group. OPG is a fully integrated medical marijuana business licensed under the provisions of the Arizona Medical Marijuana Act. Its assets include the Chino Valley MMJ Dispensary and fully established Patient Group, which since 2012 has operated as "Organica Patient Group" in Chino Valley. OPG also operates a 26,000-square-foot indoor cultivation and processing center along with a 56,600-square-foot greenhouse in Prescott Valley; has its own branded products and wholesale operations which includes distribution to more than 25% of the dispensaries in Arizona; and has exclusive manufacturing and licensing agreements with Fire Brand, Gas Extracts and Donuts Concentrate products distributed within Arizona.

Michigan – LOIs to invest in multiple strategically located properties that have or are eligible for municipal approvals for provisioning centers in Michigan. The company is currently evaluating 10 to 15 additional municipally approved locations in Michigan that would substantially increase the company's overall presence in the U.S. cannabis space.

Washington State – LOI to purchase assets from PDT Technologies LLC, including extraction and production equipment and rights to lease the current production facility in Port Townsend, Wash. The LOI includes licensing rights to produce Chong's Choice Brand CO2 Vape Cartridges, one of the leading and most recognizable brands in the cannabis space. Expansion plans include construction of a new ISO designed extraction clean room and GMP lab facility with new, highly specialized equipment with two extraction lines. The facility could produce up to 20,500 kg of cannabis concentrate on an annual basis.

Hivemind Refinery – LOI to invest in a 70% interest of Hivemind Refinery, an established line of CBD-based wellness products in the United States. The investment into Hivemind expands Nabis' investment portfolio to CBD edibles, water, drops, lotions, and other CBD wellness products across the spectrum. Nabis anticipates Hivemind will be a premium consumer CBD line to be distributed across the U.S. and Canada and will focus on products utilizing locally grown, premium CBD along with unique formulations and delivery systems.

Bloombox – binding term sheet with Momentum Ideas Co. to acquire certain assets used and marketed under the brand "Bloombox," a leading intelligent retail cannabis software platform that includes the Bloombox Software and data platform. The acquisition of Bloombox will create a dominating presence in the U.S. cannabis market, featuring an integrated ecosystem of modern, next-generation cannabis technology. Bloombox is one of the world's first standards-based cannabis software systems, enabling frictionless integration with nearly any business system or regulatory body.

Proven Management Team

CEO and Director Shay Shnet has over 20 years of experience in business and was most recently a founding partner and vice president of operations of MPX Bioceutical (CSE: MPX). While at MPX, Shnet focused on the North American cannabis space and helped build the company's portfolio of international cannabis assets. He is highly skilled in finding unique opportunities and has been directly involved with the development, branding, importing, consumer packaging and distribution of a wide variety of product lines.

President Mark Krytiuk is a very successful cannabis operator and was a founding partner of MPX. As the vice president of grow operations of MPX, he oversaw the production of medical marijuana and pharma-grade products across North America. He has been directly involved in overseeing the rapid expansion and buildout of nine facilities in three countries with budgets ranging up to $30 million. Krytiuk's experience includes consulting and working with customers to develop individual requirements for indoor and outdoor cannabis cultivation while working with federal regulators and licensing bodies to ensure compliance.

Nabis Holdings (OTC: NABIF), closed Monday's trading session at $0.145, up 16.8224%, on 25,239 volume with 14 trades. The average volume for the last 3 months is 47,866 and the stock's 52-week low/high is $0.119249999/$0.791499972.

Recent News

• Nabis Holdings Inc. (CSE: NAB) (OTC: NABIF) (FRA: 71P) Enters World’s Largest Cannabis Industry Market through Acquisition of California Dispensary
• Nabis Holdings Inc. (CSE: NAB) (OTC: NABIF) (FRA: 71P) Enters California Cannabis Market with Dispensary in Southern Desert
• Alternative Consumption Methods That Are Reshaping the Cannabis Industry - CFN Media

Endonovo Therapeutics Inc. (ENDV)

The QualityStocks Daily Newsletter would like to spotlight Endonovo Therapeutics Inc. (ENDV).

Endonovo Therapeutics Inc. (ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical™ Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.

In accord with its mission to transform the field of medicine through innovation, Endonovo’s bioelectric Electroceutical™ devices harness bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur. Endonovo’s current portfolio of commercial-stage devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke.

Flagship Therapy

SofPulse® Electroceutical ™ Therapy is an easy-to-place, non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery. Used as a stand-alone therapy or integrated into any treatment protocol, SofPulse®’s?targeted?pulsed electromagnetic field?(tPEMF)?transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. The low levels of electromagnetic fields are completely safe and are 1000 times lower than those emitted by a mobile phone.?

Because SofPulse® lessens the pain of post-surgical recovery, the patient requires far less prescription medications, thereby minimizing or eliminating the adverse side effects of narcotics and anti-inflammatory medication. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. Patients with less pain and medication may move around sooner, which further stimulates the body’s natural response to healing.

Certifications

Endonovo’s Electroceutical™ Therapy is cleared by the U.S. Federal Drug Administration (“FDA”) for the palliative treatment of pain and post-surgical edema (swelling) and is CE-marked in the European Economic Area (“EEA”) for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. The Centers for Medicare and Medicaid Services (“CMS”) has also certified Electroceutical™ Therapy for the treatment of chronic wounds.

Management

Alan Collier, Chairman and CEO
Alan Collier has more than 25 years of experience in corporate finance, IP development, telecommunications and technology, with a concentration in healthcare and technology over the past five years. Collier has served as CEO and director of IP Resources International Inc., where he was instrumental in developing a platform the for the licensing and acquisition of life science and technology companies. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Collier has previously held FINRA Series 7, 79, 63 and 24 licenses.

Michael Scott Mann, President
Michael Scott Mann has over 30 years of experience in merger and acquisitions and operational management. In 2008, Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics Inc., and led the company to become listed on the OTCBB in 2012. He was the founder, president and CEO of Frankfurt-listed U.S. Debt Settlement Inc. (USDS), where he implemented a growth by acquisition strategy.?

Don Calabria, Chief Operating Officer
Don Calabria has over 20 years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance and business development. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a bachelor’s degree from Arizona State University.

Nevena Zubcevik, Chief Medical Officer
Nevena Zubcevik, D.O., MSPT, ATC, on July 1, 2019, will lead Endonovo’s medical and clinical strategy, including the development and regulatory matters and new business development. Zubcevik, a licensed physician and educator, has more than 24 years of experience in the medical field and was an attending physician at Harvard Medical School/Partners Healthcare in the physical medicine and rehabilitation department.

Steven Ford, Vice President of Marketing
Steven Ford has 25 years of experience in the field of medical devices, including experience in sales management, product management, product development, business development and research & development at companies such as Baxter, CR Bard, Ethicon, Allergan, Mallinckrodt Pharmaceuticals and Alphatec Spine. Throughout Ford’s career, he has led and participated on over 75 product development teams and has launched over 50 medical devices globally. Ford is an innovative problem solver and has many patents in the areas of hemostasis, sealing and tissue reconstruction. Most recently, Steve was the U.S. vice president of marketing for Biom’up where he was a co-lead on the high-profile successful launch of their surgical hemostat HEMOBLAST Bellows. Steve holds a bachelor’s degree in marketing from California State University.

David Clark, Vice President of Sales
David Clark has extensive surgical device commercial experience which includes 25 years in the surgical device industry with leading companies including Medtronic and Baxter Healthcare. Most recently, Clark was the U.S. executive vice president of sales for Biom’up where he was a co-lead in the high-profile successful launch of their surgical hemostat HEMOBLAST. As part of the launch, he built and led the U.S. sales team which included over 200 in-direct sales representatives and direct commercial leadership. During his 15 years with Baxter, the BioSurgery Division grew from a small revenue business into a major market player in the advanced hemostasis space with products such as FloSeal and Tisseel. Clark has a bachelor’s degree in economics from Rutgers University.

Roc Alan McCarthy, Scientific Advisory Board Member
Roc Alan McCarthy, D.O, will help Endonovo continue to advance its clinical pipeline and contribute to the strategic and clinical development oversight of the company. McCarthy is a urologist in North Carolina, currently serving as the robotic surgeon and chairman of the robotics committee at the New Hanover Regional Medical Center.

Endonovo Therapeutics Inc. (ENDV), closed Monday's trading session at $0.0108, up 0.934579%, on 3,333,255 volume with 55 trades. The average volume for the last 3 months is 6,436,761 and the stock's 52-week low/high is $0.008999999/$0.066100001.

Recent News

• Endonovo Therapeutics Inc. (ENDV) Positioning SofPulse as Natural Post-Surgical Alternative to Opioids
• Endonovo Therapeutics Inc.’s (ENDV) SofPulse Safely Reduces Pain, Swelling
• Endonovo Therapeutics Inc. (ENDV) Delivering Safe Patient Recovery Tech as Alternative to Traditional Opioid Pain Management Solutions

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF)

The QualityStocks Daily Newsletter would like to spotlight Wildflower Brands Inc. (WLDFF).

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) is a public cannabis company developing and designing brands that focus on plant-based wellness and health products. Wildflower markets its full-spectrum CBD products to retailers in the health and wellness space throughout the United States and in legal cannabis markets in accordance with regulations marketing its THC and CBD products.

Headquartered in Vancouver, British Columbia, Canada, Wildflower employs a unique and holistic business model that encompasses research and development, manufacturing, distribution, marketing and retail. First launched in 2012 as a private company with a cannabis-focused brand, Wildflower went public in 2014 and has since reached numerous significant milestones in its drive to create brands that work in synergy toward becoming a global wellness brand leader.

Gathered within the growing family of Wildflower brands are the following entities:

• Wildflower Wellness is known for its reputable brand, uncompromising quality and mission to connect people with the healing power of plants. Wildflower Wellness offers CBD vaporizers, capsules, tinctures, soaps and topicals that are backed by a 100 percent satisfaction guarantee. Wildflower Wellness offers a full lineup of full spectrum CBD extract infused products made in the U.S. in Wildflower’s GMP facilities which are always third-party lab tested for quality assurance and accurate labeling.
• King Extracts is a California-based company focused on cannabis technology and delivery systems. The King Recharge is a discreet, 97mm small, rechargeable vaporizer with a sleek pocket-sized charging and storage case. King concentrates are clean and sophisticated blends made from CO2 extractions that are fractionally distilled for clarity and purity with proprietary terpenes blended in to deliver a robust, full-flavor profile. King products are available at 26 select, regulated retail dispensaries in California.
• Exclusive is a dispensary of high-quality cannabis products and accessories serving the city of Los Angeles, California. The company enjoys a close association with select hospital oncology departments and community programs.

Using the slogan “Plants Heal,” Wildflower’s distribution network in the U.S. includes 200+ retailers in Washington state and 20+ retailers in New York City. Wildflower has also partnered with Retail Worx to establish shop-in-shop retail locations in the heart of New York City which pairs nicely with the introduction of Wildflower into existing Bridges General’s stores in New York City and San Francisco. Through this partnership with Retail Worx, Wildflower by Bridges General stores will have exclusive product offerings in addition to the full lineup of existing Wildflower Wellness CBD products. Distribution in other U.S. markets includes 80+ wellness and healthcare practitioners with a total distribution of over 300 stores nationwide.

Wildflower holds 14 California cannabis licenses that cover recreational and medical cannabis cultivation, manufacturing, distribution and retail/delivery in the jurisdictions of California state and the city of Los Angeles. Opportunities to activate these licenses creates the phenomenal potential of driving significant revenues while minimizing risk. Expansion plans into Canada are underway with discussions centered on retail acquisitions and Wildflower launching into over-the-counter market with its CBD product line. Global expansion is a key part of Wildflower’s strategy with initial plans aimed at specific international markets where regulatory hurdles are less restrictive.

In December 2018, Wildflower began on-demand, legal and licensed cannabis delivery services to adult consumers in the Los Angeles area and has hired dozens of full-time delivery drivers to accommodate this unmet need. Wildflower has partnered with leading technology and logistics company Eaze.com to help route deliveries efficiently, manage inventory and comply with California law. Providing legal, licensed delivery services helps to ensure that all adults including those with mobility challenges and limited access to transportation services can purchase high quality, legal cannabis products.

Wildflower’s direct-to-consumer online store sales have shown an organic growth. The Company recently achieved over 300 percent growth in online sales since January 2018 with annualized revenues exceeding $1 million for online sales only, marking the ninth consecutive quarter of increased revenue.

Core Team

William MacLean is the founder and CEO of Wildflower Brands Inc. His involvement in all aspects of the business from product R&D to manufacturing setup has led the Company to its current success. MacLean is a seasoned sales professional with over 20 years of experience in various industries from advertising and marketing to medical sales. While in the advertising and marketing space, his clients included major brands including: Bell, Remax, BC Hydro, and Royal Bank.

CFO Stephen Pearce is a director and officer of a number of public companies in the resource sector. His professional experience as a practicing attorney is primarily in corporate and securities work. Pearce’s academic background includes an honors bachelor’s degree in economics from York University, in which he focused specifically on corporate finance. Pearce obtained a law degree from the University of British Columbia.

Alfred Kee, COO, is a business technology leader with over 15 years of experience in building high performing teams at small startups to large enterprises. With foundations in running large scale business critical technology and user experience product management mindset, Kee excels at guiding teams to deliver business value with agility. His knowledge and experience were honed while working with Electronic Arts, KPMG, CenturyLink, Cisco and Apple, as well as a string of successful startups. Lee brings a global perspective having lived and worked through parts of the U.S., Canada, Europe and Asia.

Creative Director Amy Yamamura is a founding member of Wildflower and has been a driving force behind the Company from the start, creating the Wildflower brand. After receiving a bachelor’s degree in communications from Boston University, Yamamura returned to Tokyo to develop her career in TV as an international business correspondent coordinating collaborative projects between top creators around the world and corporations. Yamamura’s unique experience in working closely with successful Japanese brands like UNIQLO has given her exceptional eyes for branding a company.

Wildflower Brands Inc. (WLDFF), closed Monday's trading session at $0.36, up 6.1947%, on 7,575 volume with 4 trades. The average volume for the last 3 months is 15,240 and the stock's 52-week low/high is $0.009999999/$1.12999999.

Recent News

• Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) Focuses on Expanding Suite of CBD, Hemp-Derived Products
• 420 with CNW – Study Looks at How Marijuana Extracts Can Kill Cancer Cells
• Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) Doubles Retail Reach through Dillard’s Launch